GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
IPO Year:
Exchange: NASDAQ
Website: https://www.glucotrack.com
SC 13G - Glucotrack, Inc. (0001506983) (Subject)
SC 13G - GlucoTrack, Inc. (0001506983) (Subject)
1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number
Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. "We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors," said Paul Goode, PhD, President and CEO of Glucotrack. "An entrepreneur himself, John
Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Sandie Martha has joined the Company as Vice President of Clinical Operations. "Sandie brings a wealth of knowledge and expertise to the team in leading clinical trials for both glucose monitoring and cardiology." said Paul Goode, PhD, President and CEO of Glucotrack. "The breadth and depth of
Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has appointed Andy Balo to its Board of Directors, effective immediately. Mr. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom as part of the original executive team where he remained for the next
Rutherford, NJ, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes announced today that Luis Malavé has been elected as Chairman of its Board of Directors, effective immediately. "I can think of no better person to lead our Board during this exciting and pivotal time for Glucotrack," said Andrew Sycoff, member of the Board of Directors. "With a deep commitment to the mission and values of the organization, Luis will be an invaluable strategic leader for the continued growth of the company." Mr. Malavé brings m
Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately. Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held various senior roles with Medtronic, most recently serving as Chief Financial Officer and Vice President of Finance for their $9B Neuroscience division. In addition, during her tenure at Medtronic s
Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a "best efforts" public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share. The combined offering price of each share of c
Rutherford, NJ., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the launch of a "best efforts" public offering of approximately 7,195,000 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $1.81 per share. The combined offering price of each share of comm
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024. Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings. The presentation will provide an
Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference Rutherford, NJ, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that updated preclinical data for its continuous blood glucose monitor ("CBGM") will be presented at the 24th Annual Diabetes Technology Meeting, to be held from October 15-17, 2024, in Burlingame, California. The Diabetes Technology Meeting is a highly regarded forum where the latest advancements in di
Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. "We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors," said Paul Goode, PhD, President and CEO of Glucotrack. "An entrepreneur himself, John
Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Sandie Martha has joined the Company as Vice President of Clinical Operations. "Sandie brings a wealth of knowledge and expertise to the team in leading clinical trials for both glucose monitoring and cardiology." said Paul Goode, PhD, President and CEO of Glucotrack. "The breadth and depth of
Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept Rutherford, NJ, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology innovator focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced new findings from a recent market research study evaluating the acceptance of its new Continuous Blood Glucose Monitor (CBGM) concept among people with insulin-requiring diabetes. The poster was presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference h
Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that an emerging science industry poster will be presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference to be held August 9-12, 2024 in New Orleans, LA. The Glucotrack poster will present market research data on the acceptance of the Company's Continuous Blood Glu
Rutherford, NJ, July 31, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has secured $4M in funding from its leading shareholder to support the upcoming First in Human clinical trial. "This year, we have made significant progress in the development of our groundbreaking Continuous Blood Glucose Monitor (CBGM) technology. This funding, by long-standing investor John Ballantyne, provides increased financial flexibility for the Company as we embark on human clinical trials for this less burdenso
Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has appointed Andy Balo to its Board of Directors, effective immediately. Mr. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom as part of the original executive team where he remained for the next
8-K - Glucotrack, Inc. (0001506983) (Filer)
8-K - Glucotrack, Inc. (0001506983) (Filer)
10-Q - Glucotrack, Inc. (0001506983) (Filer)
424B4 - Glucotrack, Inc. (0001506983) (Filer)
8-K - Glucotrack, Inc. (0001506983) (Filer)
EFFECT - Glucotrack, Inc. (0001506983) (Filer)
S-1/A - Glucotrack, Inc. (0001506983) (Filer)
S-1/A - Glucotrack, Inc. (0001506983) (Filer)
S-1/A - Glucotrack, Inc. (0001506983) (Filer)
S-1/A - Glucotrack, Inc. (0001506983) (Filer)
4 - GlucoTrack, Inc. (0001506983) (Issuer)
4 - GlucoTrack, Inc. (0001506983) (Issuer)
3 - GlucoTrack, Inc. (0001506983) (Issuer)
4 - GlucoTrack, Inc. (0001506983) (Issuer)
3 - GlucoTrack, Inc. (0001506983) (Issuer)
3 - GlucoTrack, Inc. (0001506983) (Issuer)
3 - GlucoTrack, Inc. (0001506983) (Issuer)
Gainers Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Bioventus (NASDAQ:BVS) stock moved upwards by 28.87% to $5.16. The market value of their outstanding shares is at $329.0 million. The company's, Q1 earnings came out today. Design Therapeutics (NASDAQ:DSGN) stock rose 28.49% to $4.69. The market value of their outstanding shares is at $264.9 million. Acutus Medical (NASDAQ:AFIB) stock moved upwards by 24.11% to $0.13. The company's market cap stands at $3.9 million. Oragenics (AMEX:OGEN) shares moved upwards by 22.78% to $1.33. The market valu
Gainers Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday. BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million. Vaccinex (NASDAQ:VCNX) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million. Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 14.19% to $8.61. The market value of their outstanding sha
Gainers GeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today. InnovAge Holding (NASDAQ:INNV) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million. Mustang Bio (NASDAQ:MBIO) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million. Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million. Seelos Therapeutics (NASDAQ:SEEL) shares increased by 4.88% to $0.29. The market
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Tecogen The Trade: Tecogen Inc. (OTC:TGEN) Director Earl R Lewis bought a total of 10,000 shares at an average price of $0.68. To acquire these shares, it cost around $6,800. The company's Director John Hatsopoulos also bought 5,000 shares. What's
Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS guidance. Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from Benzinga Pro. Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 136% to $0.3570. BranchOu
4 - GlucoTrack, Inc. (0001506983) (Issuer)